Center for Diabetes Research
Gentofte Municipality, Copenhagen, 2900, Denmark
NCT Number: NCT03246451
Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Gentofte Municipality, Copenhagen, 2900, Denmark
Aim: To evaluate the contribution of metformin-induced GLP-1 secretion on the glucose-lowering effect of metformin in patients with type 2 diabetes treated with metformin for 14 days. Furthermore, the investigators aim to elucidate the mechanisms by which metformin-induced GLP-1 secretion may affect glucose levels in patients with type 2 diabetes.
Fifteen patients with type 2 diabetes treated with lifestyle intervention and/or metformin as the only glucose-lowering drug will be enrolled in the study. The effect of a 14-day metformin treatment course on postprandial glucose tolerance will be examined with and without infusion of the GLP-1 receptor antagonist exendin9-39 in 15 patients with type 2 diabetes.
The double-blinded, placebo-controlled, randomised, cross-over study consists of four study days with concomitant infusions of A) placebo + placebo, B) placebo + exendin9-39, C) metformin + placebo and D) metformin + exendin9-39.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2-4 tablets in 14 days
1000-2000 mg in 14 days
9 mg/ml saline infusion during experimental days
Infusion of GLP-1 receptor antagonist used as a tool during experimental days
Time frame: Minutes 240
The difference between the effect of metformin on postprandial glucose tolerance (as assessed by area under curve (AUC) for plasma glucose during a standardised liquid mixed meal test) with and without blockade of GLP-1 signalling by exendin 9-39.
University Hospital, Gentofte, Copenhagen
Other
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin During Meal Ingestion in Patients With T2D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04571008
Glucose Metabolism Disorders, Metabolic Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06619834
Diabetes Mellitus, Endocrine System Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT05014204
Diabetes, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT05260021
Diabetes Mellitus, Diabetes Mellitus, Type 2
Los Angeles, California, United States
View Trial Details